Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania

About this trial

Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. The findings from this study could help identify potentially treatable factors that may improve the overall quality of life and physical functioning of patients with PAH.

Subjects will be asked to attend a baseline visit where the following will be performed:

* Measure your vital signs * Undergo a research blood draw, less than 4 tablespoons * Provide a urine pregnancy test (if applicable) * Review demographics, personal history, and medical history * Review current PAH medications * Complete questionnaires on how your PAH affects you * Complete a test of physical performance * Complete a grip strength test * Undergo an echocardiogram (Echo) * Complete a six-minute walk test * Undergo a Chest CT Scan * Undergo a scan of your body composition (DXA scan) * Obtain a weight and body composition measurement on the InBody Scale Subjects will also complete activity moniotring, two 24-hour diet recalls, and participate in remote follow-up visits every 6 months

Eligibility criteria

Qualifiers

Signed informed consent prior to initiation of any study mandated procedure.

Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification [Humbert 2022]

Idiopathic (IPAH)

Heritable (HPAH)

Disqualifiers

FEV1/FVC ≤ 5th percentile; and

FEV1 z-score < 2.5

Prior to enrollment, evidence of severe restrictive defect with

TLC < 5th percentile

Trial design

Treatments tested in this trial

  • blood draw
  • Short Performance Physical Battery
  • Grip strength test
  • Six minute walk test
  • Chest CT scan
  • Dual-Energy X-ray Absorptiometry Scan
  • Activity monitoring
  • 24 hour diet recall
  • Echocardiogram
  • Quality of Life Questionnaire (emPHasis 10)
  • International Physical Activity Questionnaire Short Form (IPAQ-SF)
  • Low resistance exercise intervention

Treatment groups

150 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Pennsylvania

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator